Fibrodysplasia (Myositis) Ossificans Progressiva

Genetics of Bone Biology and Skeletal Disease

Volumn , Issue , 2013, Pages 375-393

  Culbert, Andria L ^a   Chakkalakal, Salin A ^a   Convente, Michael R ^a   Lounev, Vitali Y ^b   Kaplan, Frederick S ^c   Shore, Eileen M ^d  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84883912209     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-387829-8.00024-X     Document Type: Chapter

References (162)

1. Pignolo RJ, Foley KL Nonhereditary heterotopic ossification. Clin Rev Bone Miner Metab 2005, 3:261-266.
2. Cohen RB, Hahn GV, Tabas JA, Peeper J, Levitz CL, Sando A, et al. The natural history of heterotopic ossification in patients who have fibrodysplasia ossificans progressiva. A study of forty-four patients. J Bone Joint Surg Am 1993, 75A(2):215-219.
3. Gregson CL, Hollingworth P, Williams M, Petrie KA, Bullock AN, Brown MA, et al. A novel ACVR1 mutation in the glycine/serine-rich domain found in the most benign case of a fibrodysplasia ossificans progressiva variant reported to date. Bone 2011, 48(3):654-658.
4. Kaplan FS, Xu M, Seemann P, Connor JM, Glaser DL, Carroll L, et al. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1. Hum Mutat 2009, 30(3):379-390.
5. Whyte MP, Wenkert D, Demertzis JL, DiCarlo EF, Westenberg E, Mumm S Fibrodysplasia ossificans progressiva: Middle-age onset of heterotopic ossification from a unique missense mutation (c.974G>C, p.G325A) in ACVR1. J Bone Miner Res 2012, 27(3):729-737.
6. Kaplan FS, Tabas JA, Gannon FH, Finkel G, Hahn GV, Zasloff MA The histopathology of fibrodysplasia ossificans progressiva. An endochondral process. J Bone Joint Surg Am 1993, 75A(2):220-230.
7. Gannon FH, Valentine BA, Shore EM, Zasloff MA, Kaplan FS Acute lymphocytic infiltration in an extremely early lesion of fibrodysplasia ossificans progressiva. ClinOrthopaed Relat Res 1998, 346:19-25.
8. Pignolo RJ, Suda RK, Kaplan FS The fibrodysplasia ossificans progressiva lesion. Clin Rev Bone Miner Metab 2005, 3(3-4):195-200.
9. Shore EM, Kaplan FS Inherited human diseases of heterotopic bone formation. Nat Rev Rheumatol 2010, 6(9):518-527.
10. McKusick VA Heritable disorders of connective tissue 1972, C.V. Mosby, St Louis, MO. 4th ed.
11. Glaser DL, Rocke DM, Kaplan FS Catastrophic falls in patients who have fibrodysplasia ossificans progressiva. Clin Orthopaed Relat Resh 1998, 346:110-116.
12. Lanchoney TF, Cohen RB, Rocke DM, Zasloff MA, Kaplan FS Permanent heterotopic ossification at the injection site after diphtheria-tetanus-pertussis immunizations in children who have fibrodysplasia ossificans progressiva. J Pediatr 1995, 126(5):762-764.
13. Luchetti W, Cohen RB, Hahn GV, Rocke DM, Helpin M, Zasloff M, et al. Severe restriction in jaw movement after routine injection of local anesthetic in patients who have fibrodysplasia ossificans progressiva. Oral Surg Oral Med Oral Pathol Oral Radiol Endodont 1996, 81(1):21-25.
14. Scarlett RF, Rocke DM, Kantanie S, Patel JB, Shore EM, Kaplan FS Influenza-like viral illnesses and flare-ups of fibrodysplasia ossificans progressiva. Clin Orthopaed Relat Res 2004, 423:275-279.
15. Kaplan FS, Tabas JA, Zasloff MA Fibrodysplasia ossificans progressiva: a clue from the fly?. Calcif Tissue Internat 1990, 47(2):117-125.
16. Connor JM, Evans DAP Fibrodysplasia ossificans progressiva. The clinical features and natural history of 34 patients. J Bone Joint Surg Br 1982, 64(1):76-83.
17. Kaplan FS, Glaser DL, Shore EM, Deirmengian G, Gupta R, Delai P, et al. The phenotype of fibrodysplasia ossificans progressiva. Clin Rev Bone Miner Metab 2005, 3(3-4):183-188.
18. Kaplan FS, Glaser DL, Hebela N, Shore EM Heterotopic ossification. J Am Acad Orthopaed Surg 2004, 12(2):116-125.
19. Kaplan FS, Shore EM Fibrodysplasia (myositis) ossificans progressiva. Primer on the metabolic bone diseases and disorders of mineral metabolism 2009, 442-446. American Society for Bone and Mineral Research, Washington, DC. 7th ed. C.J. Rosen (Ed.).
20. Kaplan FS, Shore EM, Connor JM Fibrodysplasia ossificans progressiva. Connective tissue and its heritable disorders 2002, 827-840. Wiley-Liss, New York. P. Royce, B. Steinmann (Eds.).
21. Smith R Fibrodysplasia (myositis) ossificans progressiva - Clinical lessons from a rare disease. Clin Orthopaed Relat Res 1998, (346):7-14.
22. Kaplan FS, Strear CM, Zasloff MA Radiographic and scintigraphic features of modeling and remodeling in the heterotopic skeleton of patients who have fibrodysplasia ossificans progressiva. Clin Orthopaed Relat Res 1994, (304):238-247.
23. Mahboubi S, Glaser DL, Shore EM, Kaplan FS Fibrodysplasia ossificans progressiva. Pediatr Radiol. 2001, 31(5):307-314.
24. Glaser DL, Economides AN, Wang LL, Liu X, Kimble RD, Fandl JP, et al. In vivo somatic cell gene transfer of an engineered noggin mutein prevents BMP4-induced heterotopic ossification. J Bone Joint Surg Am 2003, 85A(12):2332-2342.
25. Hegyi L, Gannon FH, Glaser DL, Shore EM, Kaplan FS, Shanahan CM Stromal cells of fibrodysplasia ossificans progressiva lesions express smooth muscle lineage markers and the osteogenic transcription factor Runx2/Cbfa-1: clues to a vascular origin of heterotopic ossification?. J Pathol 2003, 201(1):141-148.
26. Kaplan FS, Shore EM, Gupta R, Billings PC, Glaser DL, Pignolo RJ, et al. Immunological features of fibrodysplasia ossificans progessiva and the dysregulated BMP4 pathway. Clin Rev Bone Miner Metab 2005, 3(3-4):189-193.
27. Kaplan FS, Xu MQ, Glaser DL, Collins F, Connor M, Kitterman J, et al. Early diagnosis of fibrodysplasia ossificans progressiva. Pediatrics 2008, 121(5):E1295-E1300.
28. Schroeder HW, Zasloff M The hand and foot malformations in fibrodysplasia ossificans progressiva. Johns Hopkins Med J 1980, 147(2):73-78.
29. Schaffer AA, Kaplan FS, Tracy MR, O'Brien ML, Dormans JP, Shore EM, et al. Developmental anomalies of the cervical spine in patients with fibrodysplasia ossificans progressiva are distinctly different from those in patients with Klippel-Feil syndrome - Clues from the BMP signaling pathway. Spine 2005, 30(12):1379-1385.
30. Deirmengian GK, Hebela NM, O'Connell M, Glaser DL, Shore EM, Kaplan FS Proximal tibial osteochondromas in patients with fibrodysplasia ossificans progressiva. J Bone Joint Surg Am 2008, 90A(2):366-374.
31. Jiao XY, Billings PC, O'Connell MP, Kaplan FS, Shore EM, Glaser DL Heparan sulfate proteoglycans (HSPGs) modulate BMP2 osteogenic bioactivity in C2C12 cells. J Biol Chem 2007, 282(2):1080-1086.
32. O'Connell MP, Billings PC, Fiori JL, Deirmengian G, Roach HI, Shore EM, et al. HSPG modulation of BMP signaling in fibrodysplasia ossificans progressiva cells. J Cell Biochem 2007, 102(6):1493-1503.
33. Janoff HB, Zasloff MA, Kaplan FS Submandibular swelling in patients with fibrodysplasia ossificans progressiva. Otolaryngol Head Neck Surg 1996, 114(4):599-604.
34. Levy CE, Lash AT, Janoff HB, Kaplan FS Conductive hearing loss in individuals with fibrodysplasia ossificans progressiva. Am J Audiol 1999, 8(1):29-33.
35. Kaplan FS, Glaser DL Thoracic insufficiency syndrome in patients wiith fibrodysplasia ossificans progressiva. Clin Rev Bone Miner Metab 2005, 3(3-4):213-216.
36. Kaplan FS, Zasloff MA, Kitterman JA, Shore EM, Hong CC, Rocke DM Early mortality and cardiorespiratory failure in patients with fibrodysplasia ossificans progressiva. J Bone Joint Surg Am 2010, 92A(3):686-691.
37. Kussmaul WG, Esmail AN, Sagar Y, Ross J, Gregory S, Kaplan FS Pulmonary and cardiac function in advanced fibrodysplasia ossificans progressiva. Clin Orthopaed Relat Res 1998, 346:104-109.
38. Shah PB, Zasloff MA, Drummond D, Kaplan FS Spinal deformity in patients who have fibrodysplasia ossificans progressiva. J Bone Joint Surg Am 1994, 76A(10):1442-1450.
39. Einhorn T.A., Kaplan F.S. Traumatic fractures of heterotopic bone in patients who have fibrodysplasia ossificans progressiva. A report of 2 cases. 1994;(308):173-7.
40. Kaplan F, Sawyer J, Connors S, Keough K, Shore E, Gannon F, et al. Urinary basic fibroblast growth factor - A biochemical marker for preosseous fibroproliferative lesions in patients with fibrodysplasia ossificans progressiva. Clin Orthopaed Relat Res 1998, 346:59-65.
41. Shore EM, Feldman GJ, Xu M, Kaplan FS The genetics of fibrodysplasia ossificans progressiva. Clin Rev Bone Miner Metab 2005, 3(3-4):201-204.
42. Shore EM, Xu MQ, Feldman GJ, Fenstermacher DA, Brown MA, Kaplan FS, et al. A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet 2006, 38(5):525-527.
43. Hebela N, Shore EM, Kaplan FS Three pairs of monozygotic twins with fibrodysplasia ossificans progressiva. Clin Rev Bone Miner Metab 2005, 3(3-4):205-208.
44. Groppe JC, Shore EM, Kaplan FS Functional Modeling of the ACVR1 (R206H) mutation in FOP. Clin Orthopaed Relat Res 2007, 462:87-92.
45. Semonin O, Fontaine K, Daviaud C, Ayuso C, Lucotte G Identification of three novel mutations of the noggin gene in patients with fibrodysplasia ossificans progressiva. Am J Med Genet 2001, 102(4):314-317.
46. Seemann P, Mundlos S The tale of FOP, noggin and myristolation: no data, no proof!. Genet Counsel 2008, 19(3):353-355.
47. Xu MQ, Shore EM, Kaplan FS Reported noggin mutations are PCR errors. Am J Med Genet 2002, 109(2):161.
48. Bocciardi R, Bordo D, Di Duca M, Di Rocco M, Ravazzolo R Mutational analysis of the ACVR1 gene in Italian patients affected with fibrodysplasia ossificans progressiva: confirmations and advancements. Eur J Hum Genet 2009, 17(3):311-318.
49. Petrie KA, Lee WH, Bullock AN, Pointon JJ, Smith R, Russell RGG, et al. Novel mutations in ACVR1 result in atypical features in two fibrodysplasia ossificans progressiva patients. Plos One 2009, 4(3).
50. Ratbi I, Borcciadi R, Regragui A, Ravazzolo R, Sefiani A Rarely occurring mutation of ACVR1 gene in Moroccan patient with fibrodysplasia ossificans progressiva. Clin Rheumatol 2010, 29(1):119-121.
51. Barnett CP, Dugar M, Haan EA Late-onset variant fibrodysplasia ossificans progressiva leading to misdiagnosis of ankylosing spondylitis. Am J Med Genet A. 2011, 155A(6):1492-1495.
52. Carvalho DR, Navarro MMM, Martins B, Coelho K, Mello WD, Takata RI, et al. Mutational screening of ACVR1 gene in Brazilian fibrodysplasia ossificans progressiva patients. Clin Genet 2010, 77(2):171-176.
53. Furuya H, Ikezoe K, Wang LX, Ohyagi Y, Motomura K, Fujii N, et al. A unique case of fibrodysplasia ossificans progressiva with an ACVR1 mutation, G356D, other than the common mutation (R206H). Am J Med Genet A 2008, 146A(4):459-463.
54. Huse M, Chen YG, Massague J, Kuriyan J Crystal structure of the cytoplasmic domain of the type I TGF beta receptor in complex with FKBP12. Cell 1999, 96(3):425-436.
55. Chakkalakal SA, Zhang D, Culbert AL, Convente MR, Caron RJ, Wright AC, et al. An Acvr1 R206H knock-in mouse has fibrodysplasia ossificans progressiva. J Bone Miner Res 2012, 27(8):1746-1756.
56. Eivers E, Demagny H, De Robertis EM Integration of BMP and Wnt signaling via vertebrate Smad1/5/8 and Drosophila Mad. Cytokine Growth Factor Rev 2009, 20(5-6):357-365.
57. Moustakas A, Heldin CH The regulation of TGF beta signal transduction. Development 2009, 136(22):3699-3714.
58. Wharton K, Derynck R TGF beta family signaling: novel insights in development and disease. Development 2009, 136(22):3691-3697.
59. Kamiya N, Mishina Y New insights on the roles of BMP signaling in bone - a review of recent mouse genetic studies. Biofactors 2011, 37(2):75-82.
60. Lowery JW, Pazin D, Intini G, Kokabu S, Chappuis V, Capelo LP, et al. The role of BMP2 signaling in the skeleton. Crit Rev EukaryotGene Express 2011, 21(2):177-185.
61. Affolter M, Basler K The Decapentaplegic morphogen gradient: from pattern formation to growth regulation. Nat Rev Genet 2007, 8(9):663-674.
62. Ray RP, Wharton KA Twisted perspective: New insights into extracellular modulation of BMP signaling during development. Cell 2001, 104(6):801-804.
63. Twombly V, Bangi E, Le V, Malnic B, Singer MA, Wharton KA Functional analysis of saxophone, the Drosophila gene encoding the BMP type I receptor ortholog of human ALK1/ACVRL1 and ACVR1/ALK2. Genetics 2009, 183(2):563-579.
64. Langdon YG, Mullins MC Maternal and zygotic control of zebrafish dorsoventral axial patterning. Annu Rev Genet 2011, 45:357-377.
65. Little SC, Mullins MC Extracellular modulation of BMP activity in patterning the dorsoventral axis. Embryo Today Rev 2006, 78(3):224-242.
66. Shen Q, Little SC, Xu MQ, Haupt J, Ast C, Katagiri T, et al. The fibrodysplasia ossificans progressiva R206H ACVR1 mutation activates BMP-independent chondrogenesis and zebrafish embryo ventralization. J Clin Invest 2009, 119(11):3462-3472.
67. Huang XQ, Nguyen AT, Li Z, Emelyanov A, Parinov S, Gong ZY One step forward: the use of transgenic zebrafish tumor model in drug screens. Birth Defects Res C Embryo Today Rev 2011, 93(2):173-181.
68. Spoorendonk KM, Hammond CL, Huitema LFA, Vanoevelen J, Schulte-Merker S Zebrafish as a unique model system in bone research: the power of genetics and in vivo imaging. J Appl Ichthyol 2010, 26(2):219-224.
69. Yu PB, Hong CC, Sachidanandan C, Babitt JL, Deng DY, Hoyng SA, et al. Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol 2008, 4(1):33-41.
70. Collery RF, Link BA Dynamic Smad-mediated BMP signaling revealed through transgenic zebrafish. Devel Dynam 2011, 240(3):712-722.
71. Kan LX, Kessler JA Animal models of typical heterotopic ossification. J Biomed Biotechnol 2011.
72. Bragdon B, Moseychuk O, Saldanha S, King D, Julian J, Nohe A Bone morphogenetic proteins: a critical review. Cell Signal. 2011, 23(4):609-620.
73. Estrada KD, Retting KN, Chin AM, Lyons KM Smad6 is essential to limit BMP signaling during cartilage development. J Bone Miner Res 2011, 26(10):2498-2510.
74. Groppe J, Greenwald J, Wiater E, Rodriguez-Leon J, Economides AN, Kwiatkowski W, et al. Structural basis of BMP signaling inhibition by noggin, a novel twelve-membered cystine knot protein. J Bone Joint Surg Am 2003, 85A:52-58.
75. Brunet LJ, McMahon JA, McMahon AP, Harland RM Noggin, cartilage morphogenesis, and joint formation in the mammalian skeleton. Science 1998, 280(5368):1455-1457.
76. Tylzanowski P, Mebis L, Luyten FP The Noggin null mouse phenotype is strain dependent and haploinsufficiency leads to skeletal defects. Devel Dynam 2006, 235(6):1599-1607.
77. Hill CS Nucleocytoplasmic shuttling of Smad proteins. Cell Res 2009, 19(1):36-46.
78. Sieber C, Kopf J, Hiepen C, Knaus P Recent advances in BMP receptor signaling. Cytokine Growth Factor Rev 2009, 20(5-6):343-355.
79. Song B, Estrada KD, Lyons KM Smad signaling in skeletal development and regeneration. Cytokine Growth Factor Rev 2009, 20(5-6):379-388.
80. Ankeny RF, Thourani VH, Weiss D, Vega JD, Taylor WR, Nerem RM, et al. Preferential activation of SMAD1/5/8 on the fibrosa endothelium in calcified human aortic valves - Association with low BMP antagonists and SMAD6. Plos One 2011, 6(6).
81. Wallin R, Wajih N, Greenwood GT, Sane DC Arterial calcification: a review of mechanisms, animal models, and the prospects for therapy. Med Res Rev 2001, 21(4):274-301.
82. Galvin KM, Donovan MJ, Lynch CA, Meyer RI, Paul RJ, Lorenz JN, et al. A role for Smad6 in development and homeostasis of the cardiovascular system. Nat Genet 2000, 24(2):171-174.
83. Chen Q, Chen HY, Zheng DW, Kuang CZ, Fang H, Zou BY, et al. Smad7 is required for the development and function of the heart. J Biol Chem 2009, 284(1):292-300.
84. Shou WN, Aghdasi B, Armstrong DL, Guo QX, Bao SD, Charng MJ, et al. Cardiac defects and altered ryanodine receptor function in mice lacking FKBP12. Nature 1998, 391(6666):489-492.
85. Urist MR Bone: formation by autoinduction. Science 1965, 150(3698):893.
86. VolekSmith H, Urist MR Recombinant human bone morphogenetic protein (rhBMP) induced heterotopic bone development in vivo and in vitro. Proc Soc Exp Biol Med 1996, 211(3):265-272.
87. Dilling CF, Wada AM, Lazard ZW, Salisbury EA, Gannon FH, Vadakkan TJ, et al. Vessel formation is induced prior to the appearance of cartilage in BMP2-mediated heterotopic ossification. J Bone Miner Res 2010, 25(5):1147-1156.
88. Olmsted-Davis EA, Gugala Z, Gannon FH, Yotnda P, McAlhany RE, Lindsey RW, et al. Use of a chimeric adenovirus vector enhances BMP2 production and bone formation. Hum Gene Ther 2002, 13(11):1337-1347.
89. Kan LX, Hu M, Gomes WA, Kessler JA Transgenic mice overexpressing BMP4 develop a fibrodysplasia ossificans progressiva (FOP)-like phenotype. Am J Pathol 2004, 165(4):1107-1115.
90. Yoon BS, Ovchinnikov DA, Yoshii I, Mishina Y, Behringer RR, Lyons KM Bmpr1a and Bmpr1b have overlapping functions and are essential for chondrogenesis in vivo. Proc Natl Acad Sci USA 2005, 102(14):5062-5067.
91. Kobayashi T, Lyons KM, McMahon AP, Kronenberg HM BMP signaling stimulates cellular differentiation at multiple steps during cartilage development. Proc Natl Acad Sci USA 2005, 102(50):18023-18027.
92. Fukuda T, Scott G, Komatsu Y, Araya R, Kawano M, Ray MK, et al. Generation of a mouse with conditionally activated signaling through the BMP receptor, ALK2. Genesis 2006, 44(4):159-167.
93. Yu PB, Deng DY, Lai CS, Hong CC, Cuny GD, Bouxsein ML, et al. BMP type I receptor inhibition reduces heterotopic ossification. Nat Med 2008, 14(12):1363-1369.
94. Shimono K, Tung WE, Macolino C, Chi AHT, Didizian JH, Mundy C, et al. Potent inhibition of heterotopic ossification by nuclear retinoic acid receptor-gamma agonists. Nat Med 2011, 17(4):454-U491.
95. Asano K, Sakata A, Shibuya H, Kitagawa M, Teshima K, Kato Y, et al. Fibrodysplasia ossificans progressiva-like condition in a cat. J Vet Med Sci 2006, 68(9):1003-1006.
96. Guilliard MJ Fibrodysplasia ossificans in a German shepherd dog. J Small Anim Pract 2001, 42(11):550-553.
97. Hodges PC Ossification in the fetal pig - a radiographic study. Anat Rec 1953, 116(3):315-325.
98. Kaplan FS, Shore EM, Pignolo RJ, Glaser DL Animal models of fibrodysplasia ossificans progressiva. Clin Rev Bone Miner Metab 2005, 3(3-4):229-234.
99. Seibold HR, Davis CL Generalized myositis ossificans (familial) in pigs. Pathol Vet 1967, 4(1):79.
100. Valentine BA, George C, Randolph JF, Center SA, Fuhrer L, Beck KA Fibrodysplasia ossificans progressiva in the cat - a case report. J Vet Intern Med 1992, 6(6):335-340.
101. Warren HB, Carpenter JL Fibrodysplasia ossificans in three cats. Vet Pathol 1984, 21(5):495-499.
102. Yabuzoe A, Yokoi S, Sekiguchi M, Momoi Y, Ide K, Nishifuji K, et al. Fibrodysplasia ossificans progressiva in a Maine coon cat with prominent ossification in dorsal muscle. J Vet Med Sci 2009, 71(12):1649-1652.
103. Liu SK, Dorfman HD Condition resembling human localized myositis ossificans in two dogs. J Small Anim Pract 1976, 17(6):371-377.
104. Vilar JM, Ramirez G, Spinella G, Martinez A Kinematic characteristics of myositis ossificans of the semimembranosus muscle in a dog. Can Vet J Rev Vet Can 2010, 51(3):289-292.
105. Brooks DE, McCracken MD, Collins BR Heterotopic bone formation in the ciliary body of an aged guinea pig. Lab Anim Sci 1990, 40(1):88-90.
106. Brown C, Donnelly TM What's your diagnosis? Heterotopic bone in the eyes of a guinea pig. Lab Anim 2002, 31(7):23-25.
107. Griffith JW, Sassani JW, Bowman TA, Lang CM Osseous choristoma of the ciliary body in guinea pigs. Vet Pathol 1988, 25(1):100-102.
108. Williams D, Sullivan A Ocular disease in the guinea pig (Cavia porcellus): a survey of 1000 animals. Vet Ophthalmol 2010, 13:54-62.
109. Jones KB, Piombo V, Searby C, Kurriger G, Yang B, Grabellus F, et al. A mouse model of osteochondromagenesis from clonal inactivation of Ext1 in chondrocytes. Proc Natl Acad Sci USA 2010, 107(5):2054-2059.
110. Matsumoto K, Irie F, Mackem S, Yamaguchi Y A mouse model of chondrocyte-specific somatic mutation reveals a role for Ext1 loss of heterozygosity in multiple hereditary exostoses. Proc Natl Acad Sci USA 2010, 107(24):10932-10937.
111. Koziel L, Kunath M, Kelly OG, Vortkamp A Ext1-dependent heparan sulfate regulates the range of Ihh signaling during endochondral ossification. Dev Cell 2004, 6(6):801-813.
112. Morimoto K, Shimizu T, Furukawa K, Morio H, Kurosawa H, Shirasawa T Transgenic expression of the EXT2 gene in developing chondrocytes enhances the synthesis of heparan sulfate and bone formation in mice. Biochem Biophys Res Commun 2002, 292(4):999-1009.
113. Stickens D, Brown D, Evans GA EXT genes are differentially expressed in bone and cartilage during mouse embryogenesis. Dev Dynam 2000, 218(3):452-464.
114. Miyazono K, Kamiya Y, Morikawa M Bone morphogenetic protein receptors and signal transduction. J Biochem 2010, 147(1):35-51.
115. Watabe T, Miyazono K Roles of TGF-beta family signaling in stem cell renewal and differentiation. Cell Res 2009, 19(1):103-115.
116. Wu MY, Hill CS TGF-beta superfamily signaling in embryonic development and homeostasis. Dev Cell 2009, 16(3):329-343.
117. Billings PC, Fiori JL, Bentwood JL, O'Connell MP, Jiao X, Nussbaum B, et al. Dysregulated BMP signaling and enhanced osteogenic differentiation of connective tissue progenitor cells from patients with fibrodysplasia ossificans progressiva (FOP). J Bone Miner Res 2008, 23(3):305-313.
118. Shafritz AB, Shore EM, Gannon FH, Zasloff MA, Taub R, Muenke M, et al. Overexpression of an osteogenic morphogen in fibrodysplasia ossificans progressiva. N Engl J Med 1996, 335(8):555-561.
119. Miura M, Gronthos S, Zhao MR, Lu B, Fisher LW, Robey PG, et al. SHED: stem cells from human exfoliated deciduous teeth. Proc Natl Acad Sci USA 2003, 100(10):5807-5812.
120. Fiori JL, Billings PC, de la Pena LS, Kaplan FS, Shore EM Dysregulation of the BMP-p38 MAPK signaling pathway in cells from patients with fibrodysplasia ossificans progressiva (FOP). J Bone Miner Res 2006, 21(6):902-909.
121. Serrano de la Pena LS, Billings PC, Fiori JL, Ahn J, Kaplan FS, Shore EM Fibrodysplasia ossificans progressiva (FOP), a disorder of ectopic osteogenesis, misregulates cell surface expression and trafficking of BMPRIA. J Bone Miner Res 2005, 20(7):1168-1176.
122. Fukuda T, Kohda M, Kanomata K, Nojima J, Nakamura A, Kamizono J, et al. Constitutively activated ALK2 and increased SMAD1/5 cooperatively induce bone morphogenetic protein signaling in fibrodysplasia ossificans progressiva. J Biol Chem 2009, 284(11):7149-7156.
123. Little SC, Mullins MC Bone morphogenetic protein heterodimers assemble heteromeric type I receptor complexes to pattern the dorsoventral axis. Nat Cell Biol 2009, 11(5):637-U643.
124. Wang TW, Li BY, Danielson PD, Shah PC, Rockwell S, Lechleider RJ, et al. The immunophilin FKBP12 functions as a common inhibitor of the TGF beta family type I receptors. Cell 1996, 86(3):435-444.
125. Song GA, Kim HJ, Woo KM, Baek JH, Kim GS, Choi JY, et al. Molecular consequences of the ACVR1(R206H) mutation of fibrodysplasia ossificans progressiva. J Biol Chem 2010, 285(29):22542-22553.
126. van Dinther M, Visser N, de Gorter DJJ, Doorn J, Goumans M-J, de Boer J, et al. ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation. J Bone Miner Res 2010, 25(6):1208-1215.
127. Groppe JC, Wu J, Shore EM, Kaplan FS In vitro analyses of the dysregulated R206H ALK2 kinase-FKBP12 interaction associated with heterotopic ossification in FOP. Cells Tissues Organs 2011, 194(2-4):291-295.
128. Fukuda T, Kanomata K, Nojima J, Kokabu S, Akita M, Ikebuchi K, et al. A unique mutation of ALK2, G356D, found in a patient with fibrodysplasia ossificans progressiva is a moderately activated BMP type I receptor. Biochem Biophys Res Communs 2008, 377(3):905-909.
129. Ohte S, Shin M, Sasanuma H, Yoneyama K, Akita M, Ikebuchi K, et al. A novel mutation of ALK2, L196P, found in the most benign case of fibrodysplasia ossificans progressiva activates BMP-specific intracellular signaling equivalent to a typical mutation, R206H. Biochem Biophys Res Commun 2011, 407(1):213-218.
130. Gannon FH, Glaser D, Caron R, Thompson LDR, Shore EM, Kaplan FS Mast cell involvement in fibrodysplasia ossificans progressiva. Hum Pathol 2001, 32(8):842-848.
131. Moriatis JM, Gannon FH, Shore EM, Bilker W, Zasloff MA, Kaplan FS Limb swelling in patients who have fibrodysplasia ossificans progressiva. Clin Orthopaed Relat Res 1997, 336:247-253.
132. Lounev VY, Ramachandran R, Wosczyna MN, Yamamoto M, Maidment ADA, Shore EM, et al. Identification of progenitor cells that contribute to heterotopic skeletogenesis. J Bone Joint Surg Am 2009, 91A(3):652-663.
133. Hong JH, Lee GT, Lee JH, Kwon SJ, Park SH, Kim SJ, et al. Effect of bone morphogenetic protein-6 on macrophages. Immunology 2009, 128(1):e442-e450.
134. Takai S, Tokuda H, Matsushima-Nishiwaki R, Saio M, Takami T, Kozawa O TGF-beta superfamily enhances the antigen-induced IFN-gamma production by effector/memory CD8(+) T cells. Internat J Molec Med 2010, 25(1):105-111.
135. Tsai PT, Lee RA, Wu H BMP4 acts upstream of FGF in modulating thymic stroma and regulating thymopoiesis. Blood 2003, 102(12):3947-3953.
136. Salisbury E, Rodenberg E, Sonnet C, Hipp J, Gannon FH, Vadakkan TJ, et al. Sensory nerve induced inflammation contributes to heterotopic ossification. J Cell Biochem 2011, 112(10):2748-2758.
137. Kan L, Lounev VY, Pignolo RJ, Duan L, Liu Y, Stock SR, et al. Substance P signaling mediates BMP-dependent heterotopic ossification. J CellBiochem 2011, 112(10):2759-2772.
138. Bianco P Back to the future: moving beyond "mesenchymal stem cells". J Cell Biochem 2011, 112(7):1713-1721.
139. Kaplan FS, Glaser DL, Shore EM, Pignolo RJ, Xu M, Zhang Y, et al. Hematopoietic stem-cell contribution to ectopic skeletogenesis. J Bone Joint Surg Am 2007, 89A(2):347-357.
140. Medici D, Shore EM, Lounev VY, Kaplan FS, Kalluri R, Olsen BR Conversion of vascular endothelial cells into multipotent stem-like cells. Nat Med 2010, 16(12):1400-U1480.
141. Otsuru S, Tamai K, Yamazaki T, Yoshikawa H, Kaneda Y Bone marrow-derived osteoblast progenitor cells in circulating blood contribute to ectopic bone formation in mice. Biochem Biophys Res Commun 2007, 354(2):453-458.
142. Phinney DG, Prockop DJ Concise review: Mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair - Current views. Stem Cells 2007, 25(11):2896-2902.
143. Suda RK, Billings PC, Egan KP, Kim J-H, McCarrick-Walmsley R, Glaser DL, et al. Circulating osteogenic precursor cells in heterotopic bone formation. Stem Cells 2009, 27(9):2209-2219.
144. Wosczyna MN, Biswas AA, Cogswell CA, Goldhamer DJ Multipotent progenitors resident in the skeletal muscle interstitium exhibit robust BMP-dependent osteogenic activity and mediate heterotopic ossification. J Bone Miner Res 2012, 27(5):1004-1017.
145. Chen D, Zhao M, Mundy GR Bone morphogenetic proteins. Growth Factors. 2004, 22(4):233-241.
146. Goldring MB, Tsuchimochi K, Ijiri K The control of chondrogenesis. J Cell Biochem 2006, 97(1):33-44.
147. Retting KN, Song B, Yoon BS, Lyons KM BMP canonical Smad signaling through Smad1 and Smad5 is required for endochondral bone formation. Development 2009, 136(7):1093-1104.
148. Zhang DH, Schwarz EM, Rosier RN, Zuscik MJ, Puzas JE, O'Keefe RJ ALK2 functions as a BMP type I receptor and induces Indian hedgehog in chondrocytes during skeletal development. J Bone Miner Res 2003, 18(9):1593-1604.
149. Kitterman JA, Kantanie S, Rocke DM, Kaplan FS Iatrogenic harm caused by diagnostic errors in fibrodysplasia ossificans progressiva. Pediatrics 2005, 116(5):654-661.
150. Dua SG, Shah S, Purandare NC, Arora B, Rangarajan V Fibrodysplasia ossificans progressiva detected on FDG PET/CT. Clin Nuclear Med 2011, 36(10):952-954.
151. Kaplan FS, Le Merrer M, Glaser DL, Pignolo RJ, Goldsby RE, Kitterman JA, et al. Fibrodysplasia ossificans progressiva. Best Pract Res Clin Rheumatol 2008, 22(1):191-205.
152. Nussbaum BL, Grunwald Z, Kaplan FS Oral and dental health care and anesthesia for persons with fibrodysplasia ossificans progressiva. Clin Rev Bone Miner Metab 2005, 3(3-4):239-242.
153. Kaplan FS, Groppe JC, Shore EM When one skeleton is enough: approaches and strategies for the treatment of fibrodysplasia ossificans progressiva (FOP). Drug Discov Today: Ther Strat 2008, 5(4):255-262.
154. Kaplan FS, Lounev VY, Wang HT, Pignolo RJ, Shore EM, Annals NYAS Fibrodysplasia ossificans progressiva: a blueprint for metamorphosis. Skel Biol Med 2011, I:5-10.
155. Kaplan FS, Glaser DL, Pignolo RJ, Shore EM A new era for fibrodysplasia ossificans progressiva: a druggable target for the second skeleton. Expert Opin Biol Ther 2007, 7(5):705-712.
156. Hao J, Ho JN, Lewis JA, Karim KA, Daniels RN, Gentry PR, et al. In vivo structure-activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors. Acs Chem Biol 2010, 5(2):245-253.
157. Vogt J, Traynor R, Sapkota GP The specificities of small molecule inhibitors of the TGF beta and BMP pathways. Cell Signal 2011, 23(11):1831-1842.
158. Miller VM, Xia HB, Marrs GL, Gouvion CM, Lee G, Davidson BL, et al. Allele-specific silencing of dominant disease genes. Proc Natl Acad Sci USA 2003, 100(12):7195-7200.
159. Ohnishi Y, Tamura Y, Yoshida M, Tokunaga K, Hohjoh H Enhancement of allele discrimination by introduction of nucleotide mismatches into siRNA in allele-specific gene silencing by RNAi. Plos One 2008, 3(5).
160. Rodriguez-Lebron E, Paulson HL Allele-specific RNA interference for neurological disease. Gene Ther 2006, 13(6):576-581.
161. Kaplan J, Kaplan FS, Shore EM Restoration of normal BMP signaling levels and osteogenic differentiation in FOP mesenchymal progenitor cells by mutant allele-specific targeting. Gene Ther 2012, 19(7):786-790.
162. Takahashi M, Katagiri T, Furuya H, Hohjoh H Disease-causing allele-specific silencing against the ALK2 mutants, R206H and G356D, in fibrodysplasia ossificans progressiva. Gene Ther 2012, 19(7):781-785.